Literature DB >> 25582785

Local anesthetic agents for vitreoretinal surgery: no advantage to mixing solutions.

V V Jaichandran1, Rajiv Raman2, Laxmi Gella2, Tarun Sharma3.   

Abstract

PURPOSE: To compare the efficacy of lidocaine, bupivacaine, and a mixture of both in patients undergoing peribulbar anesthesia for vitreoretinal surgery.
DESIGN: Cross-sectional study. PARTICIPANTS: Ninety patients.
METHODS: Patients who underwent vitreoretinal surgery were randomized into 3 groups based on the peribulbar injection they received: lidocaine, bupivacaine, or a combination of lidocaine and bupivacaine. MAIN OUTCOME MEASURES: Time of onset of analgesia, akinesia, and intraoperative pain, if any, was noted. The efficacy of the block was graded from 0 to 5 depending on the adequacy of anesthesia and akinesia and the need for local supplementation.
RESULTS: Mean times of onset (± standard deviation) of sensory blockade for the lidocaine, bupivacaine, and combination groups were 2.14±0.18, 2.19±0.13, and 2.17±0.11 minutes, respectively (P = 0.103). Mean times of onset (± standard deviation) of motor blockade for the lidocaine, bupivacaine, and combination groups were 3.04±1.81, 4.04±2.68, and 3.38±2.48 minutes, respectively (P = 0.255). Mean time of onset of intraoperative pain for the bupivacaine group, 149.33±46.33 minutes, was prolonged significantly compared with that of the combination group, 115.83±34.49 minutes, and that of the lidocaine group, 94.17±49.86 minutes (P < 0.001). Adequate anesthesia and akinesia (grade 5) were achieved in 56.7% of the patients in the bupivacaine group compared with 23.3% in the lidocaine group and 30% in the combination group (P = 0.049).
CONCLUSIONS: In peribulbar anesthesia, 0.5% bupivacaine solution provides better quality of anesthesia than does combination 2% lidocaine and 0.5% bupivacaine in patients undergoing vitreoretinal surgery.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25582785     DOI: 10.1016/j.ophtha.2014.11.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Efficacy and safety of trans-sub-Tenon's retrobulbar anesthesia for pars plana vitrectomy: a randomized trial.

Authors:  Qian Xu; Meiqing Ren; Juanjuan Guan; Guihong Shi; Yan Ni; Jie Luan
Journal:  BMC Ophthalmol       Date:  2022-06-30       Impact factor: 2.086

2.  Reducing perceived pain levels during nonbreast lymphoscintigraphy.

Authors:  Mickaila J Johnston; James A Ntambi; Nicki Hilliard; Horace J Spencer; Rita Vaughn; Shawna S Owens; Rebecca S Myrick; Larry D Parker; Douglas A Garner; Tracy L Yarbrough
Journal:  Clin Nucl Med       Date:  2015-12       Impact factor: 7.794

3.  A prospective, randomised, double-masked comparison of local anaesthetic agents for vitrectomy.

Authors:  Ya-Li Zhou; Yao Tong; Yi-Xiao Wang; Pei-Quan Zhao; Zhao-Yang Wang
Journal:  Br J Ophthalmol       Date:  2017-02-07       Impact factor: 4.638

4.  A prospective comparison of the efficacy of 0.5% bupivacaine vs 0.75% ropivacaine in peribulbar anesthesia for vitreoretinal surgery.

Authors:  V V Jaichandran; Sangeetha Srinivasan; Sonali Raman; V Jagadeesh; Rajiv Raman
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

5.  Efficacy and safety of ropivacaine HCl in peribulbar anaesthesia for cataract surgery in patients with myotonic dystrophy type 1.

Authors:  Alberto Palladino; Maddalena De Bernardo; Marianna Scutifero; Michele Lanza; Silvio De Querquis; Nicola Rosa; Luisa Politano
Journal:  Acta Myol       Date:  2020-06-01

6.  Preventive Analgesia, Hemodynamic Stability, and Pain in Vitreoretinal Surgery.

Authors:  Michał Jan Stasiowski; Aleksandra Pluta; Anita Lyssek-Boroń; Magdalena Kawka; Lech Krawczyk; Ewa Niewiadomska; Dariusz Dobrowolski; Robert Rejdak; Seweryn Król; Jakub Żak; Izabela Szumera; Anna Missir; Przemysław Jałowiecki; Beniamin Oskar Grabarek
Journal:  Medicina (Kaunas)       Date:  2021-03-12       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.